Azitra vs Alaunos Therapeutics
AZTR and TCRT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AZTR and TCRT compare
Azitra is the larger company, worth 8.7 times as much as Alaunos Therapeutics ($36.8M against $4.2M).
Alaunos Therapeutics scores higher on the StockData Score (4 against 1 for Azitra), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AZTR | TCRT |
|---|---|---|
| Size and price | ||
| Market cap | $36.8M | $4.2M |
| Share price | $0.608 | $1.66 |
| Change, 1 year | 67.0% | −44.1% |
| Change, 5 years | – | −99.2% |
| Beta (5Y) | – | −2.45 |
| Employees | 13 | 1 |
| StockData Score | ||
| Total score | 1 | 4 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 1 | 4 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 1406× |
| P/B | 5.0× (better) | 6.5× |
| FCF yield | −30.3% | – |
| Growth | ||
| Revenue growth (TTM) | – | −50.0% |
| Profitability | ||
| Operating margin | – | −135267% |
| Net margin | – | −133667% |
| Return on equity | −257% | −186% (better) |
| Return on invested capital | −1090% | −489% (better) |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −1164.7× | – |
| Current ratio | 4.86 (better) | 0.77 |
| Altman Z-score | −1.70 (better) | −861.74 |
| Piotroski F-score | 1 | 3 (better) |
| Dividends and buybacks | ||
| Buyback yield | −14.8% | – |
| Shareholder yield | −14.8% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 35.7% | 3.6% |
| Held by insiders | 9.6% | 69.8% |
| Short interest, % of float | 0.56% | 24.0% |
Go deeper
- AZTR stock overview
- AZTR income statement
- AZTR valuation and score
- TCRT stock overview
- TCRT income statement
- TCRT valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.